Under the terms of the agreement, SSI has granted Sanofi pasteur a license to its technology with regard to the use of certain fusion proteins in the development of a tuberculosis (TB) vaccine. The license from SSI includes access to the Intercell IC31 adjuvant. If the development is successful, Sanofi pasteur would manufacture the vaccine commercially.
Wayne Pisano, president and CEO of Sanofi Pasteur, said: “Sanofi pasteur and SSI are joining forces to develop a vaccine that may have a major impact on global health by preventing a disease that currently infects one person in the world every second.”